Aimmune Therapeutics (AIMT) stock is down -36.6% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. Stock Score Report, InvestorsObserver’s proprietary scoring system, gives AIMT stock a score of 32 out of a possible 100.
That score is chiefly influenced by a short-term technical score of 1. AIMT’s score also includes a long-term technical score of 16. The fundamental score for AIMT is 81. In addition to the average rating from Wall Street analysts, AIMT stock has a mean target price of $54.17. This means analysts expect the stock to climb 197.96% over the next 12 months.
What’s Happening with AIMT Stock Today
Aimmune Therapeutics Inc (AIMT) stock is down -8.6% while the S&P 500 is higher by 0.04% as of 3:17 PM on Thursday, Jul 11. AIMT is down -$1.71 from the previous closing price of $19.89 on volume of 1,911,658 shares. Over the past year the S&P 500 has gained 7.18% while AIMT is down -36.63%. AIMT lost -$3.67 per share in the over the last 12 months.